Tevogen Bio Holdings Inc. (TVGN) Income Statement
TVGN FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsTVGN revenue and net income
TVGN growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TVGN quarterly EPS vs estimates
Tevogen Bio beat the analyst EPS estimate in 3 of the last 5 quarters. Next report: November 13, 2026 (estimate $-2.50).
TVGN income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $403,581 | $378,357 | — | — |
| Gross profit | — | −$403,581 | −$378,357 | — | — |
| Research & development | $11.1M | $31.0M | $4.4M | $5.8M | $3.0M |
| Sales, general & admin | $15.0M | $22.5M | $2.3M | $953,083 | $1.7M |
| Total operating expenses | $26.1M | $53.2M | $8.5M | $953,083 | $4.6M |
| Operating income | −$26.1M | −$53.6M | −$8.8M | −$953,083 | −$4.6M |
| Interest expense | $195,618 | $184,037 | $256,031 | $0 | $598,502 |
| Income before taxes | −$26.3M | −$13.7M | −$60.5M | $4.4M | −$15.6M |
| Income taxes | — | — | $255,867 | −$230,823 | −$9.8M |
| Net income | −$26.3M | −$10.1M | −$60.5M | $4.4M | −$15.6M |
| EBITDA | −$25.6M | −$13.1M | −$58.9M | $4.6M | −$15.0M |
| EPS (diluted) | −$12.59 | −$6.79 | −$3.96 | $2.19 | $0.00 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $396,586 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $60,144 | $59,051 | $85,786 | $27,225 | $290,784 | $103,547 | — | $101,741 | $99,990 | $98,303 | $100,869 | $93,579 |
| Gross profit | −$60,144 | −$59,051 | −$85,786 | −$27,225 | −$290,784 | −$103,547 | — | −$101,741 | −$99,990 | −$98,303 | −$100,869 | −$93,579 |
| Research & development | $3.3M | $3.1M | $2.1M | $3.1M | $2.7M | $3.2M | $2.8M | $3.3M | $4.1M | $20.8M | $908,049 | $1.1M |
| Sales, general & admin | $2.4M | $2.3M | $2.5M | $2.6M | $2.7M | $7.2M | $6.6M | $2.8M | $4.5M | $8.7M | $933,394 | $1.2M |
| Total operating expenses | $5.6M | $5.3M | $4.5M | $5.7M | $5.4M | $10.4M | $9.4M | $6.0M | $8.5M | $29.4M | $1.9M | $2.2M |
| Operating income | −$5.7M | −$5.4M | −$4.6M | −$5.7M | −$5.4M | −$10.4M | −$9.4M | −$6.1M | −$8.6M | −$29.5M | −$2.0M | −$2.3M |
| Interest expense | $98,387 | $71,166 | $70,674 | $62,340 | $38,033 | $24,571 | $15,798 | $12,459 | $6 | $155,786 | $256,031 | $299,943 |
| Income before taxes | −$5.8M | −$5.4M | −$4.7M | −$5.7M | −$5.5M | −$10.4M | −$9.5M | −$5.9M | −$9.7M | $11.3M | −$3.6M | −$3.9M |
| Income taxes | — | — | — | — | — | $60,000 | — | −$5.9M | −$3.6M | $48.6M | −$44,094 | −$39,735 |
| Net income | −$5.8M | −$5.4M | −$4.7M | −$5.7M | −$5.5M | −$10.4M | −$9.4M | −$5.9M | −$6.1M | $11.3M | −$3.6M | −$3.9M |
| EBITDA | −$5.6M | −$5.5M | −$4.5M | −$5.4M | −$5.5M | −$10.2M | — | −$5.8M | −$9.6M | $11.5M | −$3.2M | −$3.5M |
| EPS (diluted) | −$1.52 | −$1.61 | −$7.96 | −$1.50 | −$1.50 | −$3.50 | −$0.05 | −$1.74 | −$0.04 | −$0.26 | −$2.77 | −$0.88 |
| Gross margin | — | — | — | — | — | −26.1% | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | −2,611.4% | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | −2,614.1% | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TVGN's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TVGN financial results
Tevogen Bio reported no revenue in fiscal year 2026 (ended June 30, 2026). It had a net loss of $26.3 million. Diluted earnings per share came to −$12.59.
See the TVGN stock overview for the latest quote and news, or the TVGN chart for price history and technical indicators.
TVGN income statement FAQ
Does Tevogen Bio have revenue?
Tevogen Bio reported no revenue for fiscal year 2026, which ended on June 30, 2026.
Is Tevogen Bio profitable?
No. Tevogen Bio reported a net loss of $26.3 million in fiscal 2026.
How much does Tevogen Bio spend on research and development?
Tevogen Bio spent $11.1 million on research and development in fiscal 2026.
What are Tevogen Bio's earnings per share?
Tevogen Bio earned $-12.59 per diluted share in fiscal 2026, compared with $-6.79 a year earlier.
When will Tevogen Bio report its next earnings?
Tevogen Bio is expected to report results for the quarter ending September 30, 2026 on November 13, 2026 after the market closes.
When does Tevogen Bio's fiscal year end?
Tevogen Bio's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on March 31, 2026.